atn-161
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00131651)
Timeline
Indications
Mechanism of action
- Integrin alpha-5/beta-1ANTAGONIST
Integrin alpha-5/beta-1 antagonist
Binds to β subunit.
- Integrin alpha-V/beta-3ANTAGONIST
Integrin alpha-V/beta-3 antagonist
Binds to β subunit.
- Fibronectin receptor betaINHIBITOR
ITGB1 inhibitor
- Fibronectin receptor alphaINHIBITOR
ITGA5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O- Mol. weight
- 597.66 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297456 ↗
Also known as
- atn-161
- atn-161
- atn-161
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00352313 | Phase 1/Phase 2 (Phase 2) | May 1, 2006 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00131651 | Phase 2 | Aug 1, 2005 | Attenuon |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Attenuon | For profit | 1 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2006 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2006 |
3 organizations
Page 1 / 1